Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Hemu Gene logo — company profile

Hemu Gene

Founded 2021 Series A Total: $30.00M Biopharma, Biotechnology +1

General Information

Company Name Hemu Gene
Founded Year 2021
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Hemu Gene. To contact Hemu Gene, visit hemogen.cn.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Hemu Gene

Hemu Gene is a biotech startup that was founded in 2021. The company specializes in developing gene therapy technology targeting hemoglobin diseases. It boasts robust research and development capabilities and a reliable quality management system. Hemu Gene primarily utilizes two principal gene editing platforms—lentivirus and CRISPR\/Cas. Dedicated to the research, creation, and application of gene therapy vectors and genetic engineering technology, the company has also established hematopoietic stem gene therapy production lines. Hemu Gene is actively engaged in international clinical collaborations and registration declarations, indicating its commitment to global impact. Recently, the company secured a significant CNY30.00M Series A investment on 15 August 2022, with funding from 华大共赢, BGI, and COWIN. This recent investment signals confidence in Hemu Gene's potential and marks a milestone in its journey towards combating hemoglobin diseases.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A CNY30.00M 1
华大共赢 BGI COWIN
华大共赢 BGI COWIN
15 Aug 2022

Hemu Gene Alternatives & Competitors

Hemu Gene vs
Homology Medicines
Homology Medicines

Dedicated to addressing the root cause of rare genetic diseases and promising hope for patients in n...

Post-IPO Equity
Biotechnology, Health Care
Hemu Gene vs
Orchard Therapeutics - U.S.
Orchard Therapeutics - U.S. United Kingdom

Dedicated to transforming the lives of patients with severe and other genetic diseases through innov...

Post-IPO Equity
238 employees
Biotechnology, Health Care
Hemu Gene vs
CRISPR Therapeutics
CRISPR Therapeutics United States

Gene-based medicines for patients with serious diseases

IPO
350 employees
Biopharma, Biotechnology

FAQ About Hemu Gene

Hemu Gene specializes in the development of gene therapy technology designed to address hemoglobin diseases. With robust research and development capabilities and a dependable quality management system, the company utilizes two principal gene editing platforms—lentivirus and CRISPR/Cas. Hemu Gene is...
Hemu Gene was founded in 2021.
Hemu Gene operates in Biopharma, Biotechnology and Health Care.
Hemu Gene has completed 1 funding round, raising a total of $30.00M. The latest funding stage is Series A.
Top alternatives and competitors to Hemu Gene include Homology Medicines, Orchard Therapeutics - U.S., CRISPR Therapeutics, Tessera Therapeutics, BRL Medicine 邦耀生物. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Hemu Gene and Homology Medicines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Hemu Gene, https://bouncewatch.com/company/hemu-gene, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes